See more : Akshar Spintex Limited (AKSHAR.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Novus Acquisition & Development Corp. (NDEV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novus Acquisition & Development Corp., a leading company in the Insurance – Diversified industry within the Financial Services sector.
- PT VKTR Teknologi Mobilitas Tbk (VKTR.JK) Income Statement Analysis – Financial Results
- Mitsui & Co., Ltd. (MITSF) Income Statement Analysis – Financial Results
- Cohn Robbins Holdings Corp. (CRRCF) Income Statement Analysis – Financial Results
- Melar Acquisition Corp. I Warrant (MACIW) Income Statement Analysis – Financial Results
- Mirage Energy Corporation (MRGE) Income Statement Analysis – Financial Results
Novus Acquisition & Development Corp. (NDEV)
About Novus Acquisition & Development Corp.
Novus Acquisition & Development Corp., through its subsidiary, WCIG Insurance Service, Inc., operates as an insurance company in California It offers health policies in CBD concentrate cannabis space; benefit plans, such as dental vision, hearing, and telemedicine; and THC health plans. The company was formerly known as BrandQuest Development Group, Inc. and changed its name to Novus Acquisition & Development Corp. in April 2009. Novus Acquisition & Development Corp. was incorporated in 1996 and is based in Miami, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 341.93K | 305.72K | 266.43K | 242.38K | 219.24K | 180.17K | 130.43K |
| Cost of Revenue | 0.00 | 0.00 | 64.71K | 61.45K | 53.62K | 0.00 | -1.00 |
| Gross Profit | 341.93K | 305.72K | 201.72K | 180.93K | 165.62K | 180.17K | 130.43K |
| Gross Profit Ratio | 100.00% | 100.00% | 75.71% | 74.65% | 75.54% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 12.96K | 13.47K | 30.08K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 170.91K | 159.74K | 149.95K | 0.00 | 0.00 |
| SG&A | 194.42K | 188.19K | 170.92K | 159.76K | 149.98K | 84.26K | 65.53K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 194.42K | 188.19K | 170.92K | 159.76K | 149.98K | 84.26K | 65.53K |
| Cost & Expenses | 194.42K | 188.19K | 170.92K | 159.76K | 149.98K | 84.26K | 65.53K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | 228.49K | -95.51K | -82.63K | -69.26K | 161.14K | 52.52K |
| EBITDA | 147.51K | 117.54K | 0.00 | 0.00 | 1.00 | 95.91K | 64.90K |
| EBITDA Ratio | 43.14% | 38.45% | 35.85% | 34.09% | 31.59% | 53.23% | 49.76% |
| Operating Income | 147.51K | 117.54K | 95.51K | 82.63K | 69.26K | 95.91K | 64.90K |
| Operating Income Ratio | 43.14% | 38.45% | 35.85% | 34.09% | 31.59% | 53.23% | 49.76% |
| Total Other Income/Expenses | 1.00 | -1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 |
| Income Before Tax | 147.51K | 117.54K | 95.51K | 82.63K | 69.26K | 95.91K | 64.90K |
| Income Before Tax Ratio | 43.14% | 38.45% | 35.85% | 34.09% | 31.59% | 53.23% | 49.76% |
| Income Tax Expense | -167.90K | -228.49K | 95.51 | 82.63 | 69.26 | -161.14K | -52.52K |
| Net Income | 147.51K | 117.54K | 95.51K | 82.63K | 69.26K | 95.91K | 64.90K |
| Net Income Ratio | 43.14% | 38.45% | 35.85% | 34.09% | 31.59% | 53.23% | 49.76% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 107.80M | 107.80M | 107.80M | 100.95M | 101.45M | 97.85M | 97.23M |
| Weighted Avg Shares Out (Dil) | 107.80M | 107.80M | 107.80M | 100.95M | 101.45M | 97.85M | 97.23M |
Novus Releases 2Q Results, Underscores Independent Organic Growth In Cannabis
Branded Legacy and Novus Partner to Develop Plant-Based Meds for Health Plans
Source: https://incomestatements.info
Category: Stock Reports